The acute renal failure market size reached a value of USD 38,910.0 million across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 59,254.6 million by 2035, exhibiting a growth rate (CAGR) of 3.9% during 2025-2035.

Acute renal failure, commonly referred to as Acute Kidney Injury, is a sudden and usually temporary reduction in kidney function, with the onset initiated in hours to days. This abrupt interruption causes the kidneys to lose their capacity to effectively clear wastes, extra fluid, and electrolytes from the blood. This results in an accumulation of wastes, irregular chemical balance in the body, and symptoms like low urine flow, swelling in the legs, tiredness, eventually culminating in chest pain, or confusion. It is a major clinical challenge, especially in intensive care; the injury also affects the kidneys, in turn affecting other vital organs.

What is the trend in acute renal failure?

A number of key drivers are driving the growth of the acute renal failure market. One key driver is the growing worldwide incidence of chronic diseases, including diabetes and hypertension. Both diseases are leading risk factors for AKI development, and as they continue to rise, they directly increase the patient population at risk for acute kidney injury. With lifestyle diseases on the rise worldwide, demand for solutions in managing and preventing effective AKI naturally follows.

The fast-growing world geriatric population is the other key driver. Older people are more vulnerable to kidney diseases, including AKI, by virtue of their age-related physiological alterations and increased risk of comorbid conditions. This population trend assures long-term growth in AKI cases and thus maintains and drives market growth for associated therapies and diagnostics.

Increased awareness of AKI among medical practitioners and the lay community, in addition to improved diagnostic technologies, is causing the diagnosis to be made at earlier stages. Early diagnosis is critical in enhancing patient survival and reducing the risk of serious complications, and this translates into the use of superior diagnostic equipment and resultant therapy. This trend represents a strategic move away from simply responding to the symptoms of AKI to being more proactive and predictive. The streamlined regulatory pathways for new agents and digital therapeutics also enable this transition, creating new market segments with risk assessment and prevention opportunities outside of traditional acute care markets. This also suggests greater embedding of AKI prevention in managing chronic diseases such as diabetes and hypertension.

Request to get a PDF Sample Report: https://www.imarcgroup.com/acute-renal-failure-market/requestsample

The report also provides a detailed analysis of the current acute renal failure marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview

• Mechanism of Action

• Regulatory Status

• Clinical Trial Results

• Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the acute renal failure market has been studied in the report with the detailed profiles of the key players operating in the market.

• Novartis Pharmaceuticals

• Guard Therapeutics

• Sentien Biotechnologies

• AM-Pharma Holding

• Angion Biomedica

7 Major Countries Covered

• United States

• Germany

• France

• United Kingdom

• Italy

• Spain

• Japan

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-631-791-1145